Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects

NCT06774313 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06774313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06774313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
January 22, 2025
Completion date
April 8, 2026
Enrollment
73 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer